Placebo Effect on Cycling Performance: Laboratory Crossover Study
2026년 9월 15일 업데이트: Poznan University of Physical Education
The Impact of Expectations on Physical Performance and Psychophysiological Potential: a Randomized, Double-blind, Placebo-controlled Crossover Study on the Placebo Effect in the Context of Caffeine Supplementation
This study aims to determine the impact of the placebo (PLA) effect on physical and cognitive performance in a controlled laboratory setting.
The study investigates how expectations and beliefs about substance intake (caffeine vs. placebo) interact with actual consumption to influence performance and physiological stress markers.
Healthy adults (n = 80) will participate in four testing sessions using a randomized, double-blind, placebo-controlled crossover design.
Physiological stress markers (cortisol and alpha-amylase), heart rate, and performance metrics will be monitored during a standardized cycling exercise protocol.
This phase provides the dense mechanistic data required to refine a mathematical model of the placebo effect, offering insights into how individual personality traits and cognitive anchoring influence psychophysiological potential.
연구 개요
상세 설명
This study employs a randomized, double-blind, placebo-controlled crossover design to conduct a multifactorial analysis of psychophysiological and biomechanical dynamics.
Participants (n = 80, aged 20-35 years) will complete four experimental sessions separated by 7-day washout periods, involving caffeine (6 mg/kg) or placebo administration.
The laboratory protocol (160 minutes) integrates multiple modalities: (1) cognitive testing (Reaction Time Test and Flanker Test), (2) postural control assessment using the BTrackS Balance Plate, and (3) a standardized cycle ergometer exercise protocol consisting of 15 minutes at the anaerobic threshold followed by a 5-minute self-paced maximal effort trial.
Belief manipulation (immediate vs. retrospective reporting) and cognitive anchoring (feedback conditions) are implemented to isolate expectancy-driven effects.
Continuous metabolic and cardiorespiratory data collected using the Cosmed K5 system will be synchronized with blood biomarkers (lactate, glucose, caffeine, and paraxanthine) and salivary biomarkers (cortisol, testosterone, and alpha-amylase).
Advanced statistical methods, including Functional Data Analysis (FDA) and machine learning, will be used to integrate physiological trajectories with behavioral predictors.
연구 유형
중재적
등록 (추정된)
80
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Jakub Malik, PhD
- 전화번호: +48739975701
- 이메일: malik@awf.poznan.pl
연구 장소
-
-
Wielkopolska
-
Poznan, Wielkopolska, 폴란드
- Poznań University of Physical Education
-
연락하다:
- Jakub Malik, PhD
- 전화번호: +48739975701
- 이메일: malik@awf.poznan.pl
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
예
설명
Inclusion Criteria:
- Age between 20 and 35 years,
- Healthy adults,
- Regular physical activity, but not professional athletes,
- Normal or corrected-to-normal vision,
- Habitual caffeine consumption.
Exclusion Criteria:
- History of neurological, psychiatric, cardiovascular, or metabolic disorders,
- Current use of medication or supplements affecting the central nervous system,
- Musculoskeletal injuries that would impair physical performance,
- No habitual caffeine consumption or severe negative side effects of caffeine,
- Diagnosed sleep disorders or chronic fatigue,
- Diagnosed major depressive disorder or other severe psychiatric conditions,
- Presence of any menstrual disorders,
- Inability to attend all experimental study visits.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Sequence AABB
Participants follow the sequence: Caffeine, Caffeine, Placebo, Placebo, with a 7-day washout period between sessions.
|
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
|
|
실험적: Sequence BBAA
Participants follow the sequence: Placebo, Placebo, Caffeine, Caffeine, with a 7-day washout period between sessions.
|
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
|
|
실험적: Sequence ABAB
Participants follow the sequence: Caffeine, Placebo, Caffeine, Placebo, with a 7-day washout period between sessions.
|
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
|
|
실험적: Sequence BABA
Participants follow the sequence: Placebo, Caffeine, Placebo, Caffeine, with a 7-day washout period between sessions.
|
Anhydrous caffeine administered in an encapsulated form at a dosage of 6 mg per kilogram of body mass, 60 minutes before the exercise protocol.
Corn starch administered in an identical encapsulated form as the active caffeine, 60 minutes prior to the laboratory exercise protocol.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Physical Work Capacity (total work in J)
기간: Measured during each laboratory exercise protocol (approximately 85-120 minutes).
|
Total physical work performed, expressed in Joules (J), during the standardized laboratory exercise protocol, including both the Anaerobic Threshold phase and the Self-paced Maximal Time-trial.
|
Measured during each laboratory exercise protocol (approximately 85-120 minutes).
|
|
Postural Control (mm)
기간: Measured continuously during the exercise protocol and at T1 (minute 2), T2 (minute 55), and T3 (minute 125).
|
Center of Pressure excursions measured using the BTrackS Balance Plate and expressed in millimeters (mm).
|
Measured continuously during the exercise protocol and at T1 (minute 2), T2 (minute 55), and T3 (minute 125).
|
|
Explosive power variables (mm)
기간: Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
|
Explosive lower-limb power expressed in millimeters (mm) - Countermovement Jump - height.
|
Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
|
|
Psychomotor Vigilance Test Reaction Time (ms)
기간: Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
Reaction time during the Psychomotor Vigilance Test expressed in milliseconds (ms).
|
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
|
Flanker Test Reaction Time (ms)
기간: Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
Reaction time during the Flanker Test expressed in milliseconds (ms).
|
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Exercise Heart Rate (bpm)
기간: Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
|
Heart rate expressed in beats per minute (bpm) recorded continuously throughout the standardized laboratory exercise protocol.
|
Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
|
|
Exercise Heart Rate Variability (ms)
기간: Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
|
Heart rate variability expressed in milliseconds (ms) and recorded continuously throughout the standardized laboratory exercise protocol to assess autonomic regulation.
|
Measured continuously during each laboratory exercise protocol (approximately 85-120 minutes).
|
|
Simple Reaction Time (ms)
기간: Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
Reaction time during the Simple Reaction Time test expressed in milliseconds (ms).
|
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
|
Heart Rate Recovery (bpm)
기간: Measured continuously during the first 5 minutes immediately following exercise cessation.
|
Heart rate recorded during the post-exercise recovery period, expressed in beats per minute (bpm).
|
Measured continuously during the first 5 minutes immediately following exercise cessation.
|
|
Rating of Perceived Exertion (Borg Scale, points)
기간: Before and immediately after warm-up, immediately after the Anaerobic Threshold phase, immediately after the Self-paced Maximal Time-trial, and immediately after cooldown during each laboratory study visit.
|
Perceived exertion will be assessed using the Borg Rating of Perceived Exertion Scale and reported in points (6-20).
|
Before and immediately after warm-up, immediately after the Anaerobic Threshold phase, immediately after the Self-paced Maximal Time-trial, and immediately after cooldown during each laboratory study visit.
|
|
Personality Traits (NEO-FFI, points)
기간: Measured at baseline (first study visit).
|
Personality traits will be assessed using the NEO Five-Factor Inventory (NEO-FFI).
The questionnaire provides scores for five personality domains: Neuroticism, Extraversion, Openness to Experience, Agreeableness, and Conscientiousness.
Results will be reported as domain scores in points.
|
Measured at baseline (first study visit).
|
|
Mood State (POMS/BRUMS) (points)
기간: Measured during each laboratory study visit.
|
Mood state assessed using the Profile of Mood States (POMS/BRUMS), expressed in points.
|
Measured during each laboratory study visit.
|
|
Caffeine Expectancy (Caff-EQ-Brief) (points)
기간: Measured 30 minutes post-ingestion.
|
Caffeine expectancy assessed using the Caffeine Expectancy Questionnaire-Brief (Caff-EQ-Brief), expressed in points.
|
Measured 30 minutes post-ingestion.
|
|
Urine pH
기간: Measured once prior to the start of each laboratory study visit.
|
Urine pH measured using a urine strip analyzer.
|
Measured once prior to the start of each laboratory study visit.
|
|
White blood cells count and differential (count/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
White blood cells count and differential (%)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (red blood cells, RBC) (count/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (hemoglobin concentration, HGB) (mmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (hematocrit, HCT) (L/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) (fL)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (mean corpuscular hemoglobin mass, MCH) (fmol)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (mean corpuscular hemoglobin concentration, MCHC) (mmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (platelet count, PLT) (count/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (platelet hematocrit, PCT) (cL/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) (%)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Hematological indices (red blood cells distribution width - standard deviation, RDW-S) (fL)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Urea Concentration (mmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Urea concentration measured from fingertip capillary blood and expressed in mmol/L.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Glucose Concentration (mg/dL)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Glucose concentration measured from fingertip capillary blood and expressed in mg/dL.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Creatinine concentration (μmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Creatinine concentration measured from fingertip capillary blood and expressed in µmol/L.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase) (U/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of the muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase) (U/L) will be performed from fingertip capillary blood.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Lactate concentration (mmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Blood lactate concentration measured from fingertip capillary blood and expressed in mmol/L.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Electrolites' concentration (Ca, Na, K, Cl) (mmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of electrolites' concentration (Ca, Na, K, Cl) (mmol/L) will be performed from fingertip capillary blood.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Blood pH
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of gasometry markers (blood pH) will be performed from fingertip capillary blood.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Partial Pressure of Carbon Dioxide and Oxygen (pCO2, pO2) (mmHg)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of gasometry markers (pCO2, pO2) (mmHg) will be performed from fingertip capillary blood.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
CAF and PAX concentrations (µmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
Assessment of caffeine and paraxanthine concentrations (µmol/L) will be performed from fingertip capillary blood.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before exercise, and 3 minutes post-exercise.
|
|
Static weight distribution (mm)
기간: Measured at the start of each study visit.
|
Static weight distribution expressed in millimeters of Center of Pressure symmetry.
|
Measured at the start of each study visit.
|
|
Analysis of body composition (fat-free mass, fat mass) (kg)
기간: Measured at the start of each study visit.
|
Assessment of body composition (fat-free mass, fat mass) (kg) will be carried out at the start of each study visit.
|
Measured at the start of each study visit.
|
|
Analysis of body composition (total body water) (L)
기간: Measured at the start of each study visit.
|
Assessment of body composition (total body water) (L) will be carried out at the start of each study visit.
|
Measured at the start of each study visit.
|
|
Analysis of body composition (total body water) (%)
기간: Measured at the start of each study visit.
|
Assessment of body composition (total body water) (%) will be carried out at the start of each study visit.
|
Measured at the start of each study visit.
|
|
Autonomic Response during Cognitive Performance (bpm)
기간: Measured at three time points: T1 (pre-ingestion; 2 minute of protocol), T2 (post-ingestion/pre-exercise; 55 minute of protocol), and T3 (post-exercise; 125 minute of protocol).
|
Heart rate and heart rate variability recording during cognitive testing blocks, expressed in beats per minute (bpm).
|
Measured at three time points: T1 (pre-ingestion; 2 minute of protocol), T2 (post-ingestion/pre-exercise; 55 minute of protocol), and T3 (post-exercise; 125 minute of protocol).
|
|
Anthropometric Indices (kg)
기간: Measured at the start of each study visit.
|
Body mass in kilograms will be measured at the start of each study visit.
|
Measured at the start of each study visit.
|
|
Anthropometric Indices (metres)
기간: Measured at the start of each study visit.
|
Height in metres will be measured at the start of each study visit.
|
Measured at the start of each study visit.
|
|
Explosive power variables (ms)
기간: Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
|
Explosive lower-limb power variables expressed in milliseconds (ms) - Countermovement Jump - contact time and flight time.
|
Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
|
|
Explosive power variables (W)
기간: Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
|
Explosive lower-limb power expressed in Watts (W) - Countermovement Jump - power.
|
Continuous recording throughout the exercise protocol and discrete assessments at T1 (2 minute of protocol), T2 (55 minute of protocol), and T3 (125 minute of protocol).
|
|
Hydration Status (g/mL)
기간: Once prior to the start of each laboratory study visit.
|
Assessment of urine specific gravity (g/mL) using a urine strip analyzer.
|
Once prior to the start of each laboratory study visit.
|
|
Flanker Test Accuracy (%)
기간: Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
Accuracy during the Flanker Test expressed as the percentage of correct responses.
|
Measured at T1 (pre-ingestion, minute 2 of the protocol), T2 (post-ingestion/pre-exercise, minute 55 of the protocol), and T3 (post-exercise, minute 125 of the protocol).
|
|
Heart Rate Variability Recovery (ms)
기간: Measured continuously during the first 5 minutes immediately following exercise cessation.
|
Heart rate variability expressed in milliseconds (ms) during the post-exercise recovery period.
|
Measured continuously during the first 5 minutes immediately following exercise cessation.
|
|
Caffeine Expectancy Questionnaire Score (points)
기간: Measured 30 minutes post-ingestion.
|
Caffeine expectancy assessed using the Caffeine Expectancy Questionnaire and expressed in points.
|
Measured 30 minutes post-ingestion.
|
|
Suggestibility (SSS) (points)
기간: Measured during the last study visit.
|
General suggestibility assessed using the Short Suggestibility Scale (SSS), expressed in points.
|
Measured during the last study visit.
|
|
Intrinsic Motivation (IMI) (points)
기간: Measured after each test block during every laboratory study visit.
|
Task-specific intrinsic motivation assessed using the Intrinsic Motivation Inventory (IMI), expressed in points.
|
Measured after each test block during every laboratory study visit.
|
|
Sport Motivation (SMS) (points)
기간: Measured during the first study visit.
|
Sport motivation assessed using the Sport Motivation Scale (SMS), expressed in points.
|
Measured during the first study visit.
|
|
Sleep Quality (LSEQ) (points)
기간: Measured once during each laboratory study visit.
|
Subjective sleep quality assessed using the Leeds Sleep Evaluation Questionnaire (LSEQ), expressed in points.
|
Measured once during each laboratory study visit.
|
|
Salivary Cortisol Concentration (nmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
|
Salivary cortisol concentration expressed in nmol/L.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
|
|
Salivary Testosterone Concentration (pmol/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
|
Salivary testosterone concentration expressed in pmol/L.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
|
|
Salivary Alpha-amylase Activity (U/L)
기간: Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
|
Salivary alpha-amylase activity expressed in U/L.
|
Measured at baseline (pre-supplementation), 30 minutes post-ingestion, before warm-up (60 minutes post-ingestion), 3 minutes post-exercise, and 10 minutes post-exercise.
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Jakub Malik, PhD, Poznan University of Physical Education, Department of Sports Psychology
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2027년 1월 1일
기본 완료 (추정된)
2028년 3월 31일
연구 완료 (추정된)
2029년 3월 31일
연구 등록 날짜
최초 제출
2026년 7월 21일
QC 기준을 충족하는 최초 제출
2026년 7월 31일
처음 게시됨 (실제)
2026년 8월 5일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 9월 18일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 9월 15일
마지막으로 확인됨
2026년 7월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 152-2-26
- 2025/57/N/NZ4/04470 (기타 보조금/기금 번호: National Science Centre)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
예
IPD 계획 설명
The study protocol will be published as an open-access article.
Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, following the FAIR principles.
IPD 공유 기간
The study protocol will be available upon its publication.
The IPD and analytic code will be available starting from the date of the primary study results publication and will remain accessible for at least 5 years.
IPD 공유 액세스 기준
The study protocol will be published as an open-access article.
Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, in accordance with FAIR principles.
IPD 공유 지원 정보 유형
- 연구_프로토콜
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .